We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EMA:TSXEmera Incorporated Analysis

Data as of 2026-03-13 - not real-time

CA$73.17

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Emera is trading at C$73.17, essentially at its 52‑week high and comfortably above its 20‑day (C$70.75), 50‑day (C$68.98) and 200‑day (C$66.13) moving averages, confirming a bullish technical backdrop. The RSI sits at 71, signaling an overbought condition, while the MACD remains bullish with a modest histogram expansion. Volume is on a downtrend and beta is slightly negative (‑0.21), suggesting limited market‑wide sensitivity, yet 30‑day volatility is elevated at roughly 17%. The dividend yield is attractive at 4% but the payout ratio of 86% together with negative free cash flow (‑C$1.9 bn) and a debt‑to‑equity ratio above 160% raise sustainability questions.
Recent earnings highlighted record net income and a historic C$3.6 bn capex program, prompting analysts to diverge: some lift price targets toward C$74‑75, while others, citing valuation and regulatory headwinds, remain cautious around the C$69‑70 range. The DCF‑derived fair value of roughly C$31.8 implies the stock is significantly overvalued, and regulatory risk inherent to the utilities sector adds a medium‑high overlay. Given the strong dividend, stable regulated cash flows, but concerning leverage and valuation, a prudent stance is to hold while monitoring earnings, debt reduction progress, and any regulatory developments.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI overbought and price near resistance
  • High dividend yield but sustainability concerns
  • Negative free cash flow and elevated leverage

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Analyst split on price targets (C$69‑75)
  • Regulatory risk affecting rate growth
  • Potential debt reduction from cash flow improvements

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Stable regulated earnings and infrastructure assets
  • Long‑term dividend appeal despite payout ratio
  • High debt load requiring disciplined capital allocation

Key Metrics & Analysis

Financial Health

Revenue Growth13.80%
Profit Margin12.41%
P/E Ratio21.6
ROE8.17%
ROA2.96%
Debt/Equity161.12
P/B Ratio1.8
Op. Cash FlowCA$1.8B
Free Cash FlowCA$-1922875008
Industry P/E23.3

Technical Analysis

TrendBullish
RSI71.3
SupportCA$68.68
ResistanceCA$73.39
MA 20CA$70.75
MA 50CA$68.98
MA 200CA$66.13
MACDBullish
VolumeDecreasing
Fear & Greed Index72.25

Valuation

Fair ValueCA$31.77
Target PriceCA$69.82
Upside/Downside-4.58%
GradeOvervalued
TypeBlend
Dividend Yield4.02%

Risk Assessment

Beta-0.21
Volatility17.36%
Sector RiskLow
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.